bintrafusp alfa (M7824) / EMD Serono  >>  Phase 3
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
bintrafusp alfa (M7824) / EMD Serono
LUNG 037, NCT03631706 / 2018-001517-32: M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)

Checkmark Interim data from P3 INTR@PID Lung 037 trial for 1L treatment in PD-L1 expressing advanced NSCLC
Sep 2020 - Sep 2020: Interim data from P3 INTR@PID Lung 037 trial for 1L treatment in PD-L1 expressing advanced NSCLC
Checkmark Three-year follow up data from trial for PD-L1 expressing 2L NSCLC
Sep 2020 - Sep 2020: Three-year follow up data from trial for PD-L1 expressing 2L NSCLC
Checkmark 1L treatment in PD-L1 expressing advanced NSCLC
More
Active, not recruiting
3
304
Europe, Canada, Japan, US, RoW
M7824, Pembrolizumab
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Non-small Cell Lung Cancer
06/21
06/24
2021-000179-36: Bintrafusp alfa Program Rollover Study Estudio de continuación del programa Bintrafusp alfa

Ongoing
3
39
Europe
M7824, Concentrate for solution for infusion
Merck KGaA, Merck KGaA
Non-small cell lung cancer (NSCLC), biliary tract cancer (BTC), cervical cancer, and triple-negative breast cancer (TNBC) Cáncer de pulmón de células no pequeñas (NSCLC), cáncer de vías biliares (BTC), cáncer de cuello uterino y cáncer de mama triple negativo (TNBC), Non-small cell lung cancer (NSCLC), biliary tract cancer (BTC), cervical cancer, and triple-negative breast cancer (TNBC) Cáncer de pulmón de células no pequeñas (NSCLC), cáncer de vías biliares (BTC), cáncer de cuello uterino y cáncer de mama triple negativo (TNBC), Diseases [C] - Cancer [C04]
 
 
MS200647_0054, NCT05061823 / 2021-000179-36: Bintrafusp Alfa Program Rollover Study

Active, not recruiting
3
32
Europe, Japan, US, RoW
Bintrafusp alfa, M7824
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Lung Cancer, Cancer
04/25
04/25
MS200647_0055, NCT04066491 / 2019-001992-35: Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC

Hourglass Oct 2022 - Dec 2022 : Data from trial in combination with gemcitabine and cisplatin for 1L biliary tract cancer
Terminated
2/3
309
Europe, Japan, US, RoW
M7824, Placebo, Gemcitabine, Cisplatin
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer
05/21
11/22

Download Options